{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:33:31Z","timestamp":1767335611484,"version":"3.48.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Steroid-refractory acute graft-versus-host disease (SR-aGVHD) represents a severe and persistent complication that can arise following allogeneichematopoietic stem cell transplantation (allo-HSCT). This study aimed toassess the effectiveness and safety of basiliximab compared with those of a humanized anti-CD25 monoclonal antibody (xenopax) in the treatment of SR-aGVHD in patients who underwent allo-HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective trial included 32 patients diagnosed with SR-aGVHD who were administered xenopax at 1 mg\/kg on days 1, 4, and 8, and weekly thereafter until aGVHD severity was reduced to below grade 2. A historical cohort of 37 patients received basiliximab, which is a chimeric mouse-human anti-CD25 antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall response (OR) rate on day 28 was not significantly different between The xenopax and basiliximab groups, with rates of 82% and 72%, respectively (p=0.57). Additionally, no differences were observed between the groups regarding the safety profile. The 1-year overall survival (OS) and non-relapse mortality (NRM) rates in the xenopax and basiliximab cohorts were 64% versus 40% (p=0.06) and 45% versus 48% (p=0.46), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In conclusion, no significant differences were observed in efficacy or adverse events between chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for the treatment of SR-aGVHD. Further studies with larger cohorts are necessary to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1660452","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:50Z","timestamp":1767335330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for steroid-refractory acute graft-versus-host disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinhui","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease \u2014 biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003937","article-title":"Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: Risk factors and clinical outcomes","volume":"5","author":"El Jurdi","year":"2021","journal-title":"Blood Advances"},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","article-title":"Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"30","author":"Massenkeil","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705306","article-title":"Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist","volume":"37","author":"Funke","year":"2006","journal-title":"Bone marrow transplantation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.624","article-title":"CD25 blockade delays regulatory T cell reconstitution and does not prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"23","author":"Locke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1211171","article-title":"Second-line therapy for patients with steroid-refractory aGVHD: Systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Chengxin","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749266","article-title":"Meta-analysis of interleukin-2 receptor antagonists as the treatment for steroid-refractory acute graft-versus-host disease","volume":"12","author":"Mengzhu","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5414\/CN107889","article-title":"Does basiliximab induction trigger lifethreatening ARDS and shock in young patients after kidney transplantation","volume":"83","author":"Massart","year":"2015","journal-title":"Clin Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.009","article-title":"Jiang Shanshan. Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graftversus-host disease after hematopoietic stem cell transplantation","volume":"44","author":"Yaxue","year":"2023","journal-title":"Chin J Hematol"},{"key":"B11","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13925","article-title":"Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Zheng","year":"2023","journal-title":"Eur J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.017","article-title":"Outcomes and predictors of response in steroid-refractory acute graft-versus-host disease","volume":"25","author":"Rashidi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26475","article-title":"Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis","volume":"97","author":"Mo","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1660452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:51Z","timestamp":1767335331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1660452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2025.1660452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1660452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1660452"}}